Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(9)
•••
Comment by Donniebrasco57on Jan 15, 2020 9:17am
32 Views
Post# 30554777

RE:RE:RE:RE:RE:RE:RE:RE:RE:If you want shares

RE:RE:RE:RE:RE:RE:RE:RE:RE:If you want shares
Donniebrasco57 wrote:
Belgiumboy wrote:
Belgiumboy wrote:
Captainblk wrote:
Moonshiner592 wrote: Doubles - you really think Kly can hit $2+ per share?? ... in the next 2 months or so??? 


if im using real rough napkin math right, that would put a market cap of about 1 billion to get and SP of around $2. some here have suggested a buyout number being minimum of 5 billion; hearsay that its a minimum Rob is willing to do, which would place the needle closer to $9. 5 billion could be a paltry investment to some of the pharmas that myknight listed earlier today- some were north of $200 BILLION MC's. this is partly why I tried to put in a sell order for $9 last week, but got shut down by TD. we wont know until we know but the idea is tantalizing


In comparison : Kiadis pharma during phase 3 research GVHD (no other drugs in pipeline) had a market cap of 300 million USD. In case of approval it would have been probably somewhere around 900 million USD. Current Market Cap of Kalytera is 23 million CAD.... Research results of Kalytera are way better... It's not difficult to see the potential...


Doing some calculations : MC kalytera 18 million USD / MC Kiadis Pharma in case of approval 900 million USD = 1/50
Share price Kalytera 0,045cad x 50 = 2,25 cad
So in case of drug approval 2 dollar/share is not impossible! Sounds good to me! Time to load up! Go Kaly Go!!!!


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities